Overview

A Study to Evaluate the Efficacy and Safety of DA-8010 in Patients With Overactive Bladder

Status:
Not yet recruiting
Trial end date:
2024-03-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of DA-8010 in patients with overactive bladder.
Phase:
Phase 3
Details
Lead Sponsor:
Dong-A ST Co., Ltd.
Treatments:
DA-8010
Solifenacin Succinate